ANTITUSSIVE PHARMACOTHERAPY IN ACUTE COUGH: EFFICACY, SAFETY, AND CURRENT CLINICAL EVIDENCE

Background: Acute viral cough is one of the most frequent reasons for primary-care consultation, yet evidence for commonly used antitussive agents varies widely. This review synthesizes current data on the pathophysiology, efficacy, safety, and clinical recommendations guiding antitussive pharmacotherapy. Methods: This review synthesizes current evidence on antitussive pharmacotherapy in acute cough in adults and children. A narrative review of eligible publications indexed in PubMed, Scopus, and Google Scholar from 2013–2025 was conducted, prioritizing systematic reviews, randomized controlled trials, pharmacovigilance studies, and clinical guidelines. Search terms included “acute cough”, “antitussive”, “dextromethorphan”, “codeine”, “hydrocodone”, “levodropropizine”, “butamirate”, “benzonatate”, “ivy leaf”, “Pelargonium sidoides”, and “honey”. Relevant studies were screened and qualitatively analyzed. Results: Acute viral cough arises from inflammatory sensitization of airway sensory pathways and heightened brainstem cough-reflex responsiveness. Opioid antitussives demonstrate limited symptomatic benefit and present substantial safety concerns, particularly in pediatric populations. Centrally acting non-opioid agents, such as dextromethorphan, show modest and inconsistent efficacy with dose-dependent toxicity. Peripherally acting antitussives—notably levodropropizine—exhibit more consistent reductions in cough severity with favorable tolerability. Complementary agents, including ivy leaf extract, Pelargonium sidoides, and honey in children over one year, offer modest symptomatic benefit with strong safety profiles. Contemporary guidelines consistently discourage routine antitussive use and emphasize the self-limiting nature of acute viral cough. Conclusion: Evidence supports a cautious, symptom-targeted approach to pharmacologic therapy in acute viral cough, prioritizing safety and reserving antitussives for selected clinical scenarios.

Authors

Institutions

Publication Details

Journal
International Journal of Innovative Technologies in Social Science
Published
2025-12-30
DOI
https://doi.org/10.31435/ijitss.4(48).2025.4642
Primary Topic
Respiratory and Cough-Related Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ANTITUSSIVE PHARMACOTHERAPY IN ACUTE COUGH: EFFICACY, SAFETY, AND CURRENT CLINICAL EVIDENCE

Karol Grela, Karolina Nowacka, Weronika Radecka, Agnieszka Szreiber et al.
International Journal of Innovative Technologies in Social Science
Respiratory and Cough-Related Research
article

ANTITUSSIVE PHARMACOTHERAPY IN ACUTE COUGH: EFFICACY, SAFETY, AND CURRENT CLINICAL EVIDENCE

Karol Grela, Karolina Nowacka, Weronika Radecka, Agnieszka Szreiber, Anna Woźniak, Michał Ględa, Aleksandra Grygorowicz, Michał Szyszka, Kamil Jabłoński, Weronika Kozak, Klaudia Baran
article en

Abstract

Background: Acute viral cough is one of the most frequent reasons for primary-care consultation, yet evidence for commonly used antitussive agents varies widely. This review synthesizes current data on the pathophysiology, efficacy, safety, and clinical recommendations guiding antitussive pharmacotherapy. Methods: This review synthesizes current evidence on antitussive pharmacotherapy in acute cough in adults and children. A narrative review of eligible publications indexed in PubMed, Scopus, and Google Scholar from 2013–2025 was conducted, prioritizing systematic reviews, randomized controlled trials, pharmacovigilance studies, and clinical guidelines. Search terms included “acute cough”, “antitussive”, “dextromethorphan”, “codeine”, “hydrocodone”, “levodropropizine”, “butamirate”, “benzonatate”, “ivy leaf”, “Pelargonium sidoides”, and “honey”. Relevant studies were screened and qualitatively analyzed. Results: Acute viral cough arises from inflammatory sensitization of airway sensory pathways and heightened brainstem cough-reflex responsiveness. Opioid antitussives demonstrate limited symptomatic benefit and present substantial safety concerns, particularly in pediatric populations. Centrally acting non-opioid agents, such as dextromethorphan, show modest and inconsistent efficacy with dose-dependent toxicity. Peripherally acting antitussives—notably levodropropizine—exhibit more consistent reductions in cough severity with favorable tolerability. Complementary agents, including ivy leaf extract, Pelargonium sidoides, and honey in children over one year, offer modest symptomatic benefit with strong safety profiles. Contemporary guidelines consistently discourage routine antitussive use and emphasize the self-limiting nature of acute viral cough. Conclusion: Evidence supports a cautious, symptom-targeted approach to pharmacologic therapy in acute viral cough, prioritizing safety and reserving antitussives for selected clinical scenarios.

International Journal of Innovative Technologies in Social ScienceVol. 2(4(48))
Medical University of Silesia (PL), Medical University of Warsaw (PL), Medical University of Lodz (PL), Uczelnia Łazarskiego (PL), Silesian Center for Heart Disease (PL), University of Warmia and Mazury in Olsztyn (PL), Cardinal Stefan Wyszynski University in Warsaw (PL), Gdańsk Medical University (PL)
Good health and well-being
Openalex Percentile: Top 26%
Respiratory and Cough-Related Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.